期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 56, 期 16, 页码 6317-6329出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm4006274
关键词
-
资金
- Diamond Light Source [MX6683]
- Cancer-Research UK
- EPSRC [EP/I037229/1] Funding Source: UKRI
- Engineering and Physical Sciences Research Council [EP/I037229/1] Funding Source: researchfish
Development of drug resistance during cancer chemotherapy is one of the major causes of chemotherapeutic failure for the majority of clinical agents. The aim of this study was to investigate the underlying molecular mechanism of resistance developed by the mitotic kinesin Eg5 against the potent second-generation ispinesib analogue SB743921 (1), a phase I/II clinical candidate. Biochemical and biophysical data demonstrate that point mutations in the inhibitor-binding pocket decrease the efficacy of 1 by several 1000-fold. Surprisingly, the structures of wild-type and mutant Eg5 in complex with 1 display no apparent structural changes in the binding configuration of the drug candidate. Furthermore, ITC and modeling approaches reveal that resistance to 1 is not through conventional steric effects at the binding site but through reduced flexibility and changes in energy fluctuation pathways through the protein that influence its function. This is a phenomenon we have called resistance by allostery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据